Zoe Arvanitakis1, Hoau-Yan Wang2,3, Ana W Capuano1, Amber Khan2,3, Bouchra Taïb4, Frederick Anokye-Danso4, Julie A Schneider1, David A Bennett1, Rexford S Ahima4, Steven E Arnold5. 1. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois. 2. Department of Molecular, Cellular, and Biomedical Science, City University of New York School of Medicine, New York, New York. 3. Department of Biology, Neuroscience Program, Graduate School of the City University of New York, New York, New York. 4. Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Neurology and Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Abstract
OBJECTIVE: To examine associations of molecular markers of brain insulin signaling with Alzheimer disease (AD) and cognition among older persons with or without diabetes. METHODS: This clinical-pathologic study was derived from a community-based cohort study, the Religious Orders Study. We studied 150 individuals (mean age at death =87 years, 48% women): 75 with and 75 without diabetes (matched by sex on age at death and education). Using enzyme-linked immunosorbent assay, immunohistochemistry, and ex vivo stimulation of brain tissue with insulin, we assessed insulin signaling in the postmortem middle frontal gyrus cortex. Postmortem data documented AD neuropathology. Clinical evaluations documented cognitive function proximate to death, based on 17 neuropsychological tests. In adjusted regression analyses, we examined associations of brain insulin signaling with diabetes, AD, and level of cognition. RESULTS: Brain insulin receptor substrate-1 (IRS1) phosphorylation (pS307 IRS1/total IRS1) and serine/threonine-protein kinase (AKT) phosphorylation (pT308 AKT1/total AKT1) were similar in persons with or without diabetes. AKT phosphorylation was associated with the global AD pathology score (p = 0.001). In contrast, IRS1 phosphorylation was not associated with AD (p = 0.536). No other associations of insulin signaling were found with the global AD score, including when using the ex vivo brain insulin stimulation method. In secondary analyses, normalized pT308 AKT1 was positively correlated with both the amyloid burden and tau tangle density, and no other associations of brain insulin signaling with neuropathology were observed. Moreover, normalized pT308 AKT1 was associated with a lower level of global cognitive function (estimate = -0.212, standard error = 0.097; p = 0.031). INTERPRETATION: Brain AKT phosphorylation, a critical node in the signaling of insulin and other growth factors, is associated with AD neuropathology and lower cognitive function. ANN NEUROL 2020;88:513-525.
OBJECTIVE: To examine associations of molecular markers of brain insulin signaling with Alzheimer disease (AD) and cognition among older persons with or without diabetes. METHODS: This clinical-pathologic study was derived from a community-based cohort study, the Religious Orders Study. We studied 150 individuals (mean age at death =87 years, 48% women): 75 with and 75 without diabetes (matched by sex on age at death and education). Using enzyme-linked immunosorbent assay, immunohistochemistry, and ex vivo stimulation of brain tissue with insulin, we assessed insulin signaling in the postmortem middle frontal gyrus cortex. Postmortem data documented AD neuropathology. Clinical evaluations documented cognitive function proximate to death, based on 17 neuropsychological tests. In adjusted regression analyses, we examined associations of brain insulin signaling with diabetes, AD, and level of cognition. RESULTS: Brain insulin receptor substrate-1 (IRS1) phosphorylation (pS307 IRS1/total IRS1) and serine/threonine-protein kinase (AKT) phosphorylation (pT308 AKT1/total AKT1) were similar in persons with or without diabetes. AKT phosphorylation was associated with the global AD pathology score (p = 0.001). In contrast, IRS1 phosphorylation was not associated with AD (p = 0.536). No other associations of insulin signaling were found with the global AD score, including when using the ex vivo brain insulin stimulation method. In secondary analyses, normalized pT308 AKT1 was positively correlated with both the amyloid burden and tau tangle density, and no other associations of brain insulin signaling with neuropathology were observed. Moreover, normalized pT308 AKT1 was associated with a lower level of global cognitive function (estimate = -0.212, standard error = 0.097; p = 0.031). INTERPRETATION: Brain AKT phosphorylation, a critical node in the signaling of insulin and other growth factors, is associated with AD neuropathology and lower cognitive function. ANN NEUROL 2020;88:513-525.
Authors: Eric M Blalock; Richard Grondin; Kuey-chu Chen; Olivier Thibault; Veronique Thibault; Jignesh D Pandya; Amy Dowling; Zhiming Zhang; Patrick Sullivan; Nada M Porter; Philip W Landfield Journal: J Neurosci Date: 2010-04-28 Impact factor: 6.167
Authors: Hoau-Yan Wang; Ana W Capuano; Amber Khan; Zhe Pei; Kuo-Chieh Lee; David A Bennett; Rexford S Ahima; Steven E Arnold; Zoe Arvanitakis Journal: Neurobiol Aging Date: 2019-08-20 Impact factor: 4.673
Authors: Ana W Capuano; Robert S Wilson; William G Honer; Vladislav A Petyuk; Sue E Leurgans; Lei Yu; Jennifer R Gatchel; Steven Arnold; David A Bennett; Zoe Arvanitakis Journal: J Affect Disord Date: 2019-03-08 Impact factor: 4.839
Authors: Saion Chatterjee; Sanne A E Peters; Mark Woodward; Silvia Mejia Arango; G David Batty; Nigel Beckett; Alexa Beiser; Amy R Borenstein; Paul K Crane; Mary Haan; Linda B Hassing; Kathleen M Hayden; Yutaka Kiyohara; Eric B Larson; Chung-Yi Li; Toshiharu Ninomiya; Tomoyuki Ohara; Ruth Peters; Tom C Russ; Sudha Seshadri; Bjørn H Strand; Rod Walker; Weili Xu; Rachel R Huxley Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Vijay K Ramanan; Xuewei Wang; Scott A Przybelski; Sheelakumari Raghavan; Michael G Heckman; Anthony Batzler; Matthew L Kosel; Timothy J Hohman; David S Knopman; Jonathan Graff-Radford; Val J Lowe; Michelle M Mielke; Clifford R Jack; Ronald C Petersen; Owen A Ross; Prashanthi Vemuri Journal: Brain Commun Date: 2020-09-26
Authors: Caglar Cosarderelioglu; Lolita S Nidadavolu; Claudene J George; Esther S Oh; David A Bennett; Jeremy D Walston; Peter M Abadir Journal: Front Neurosci Date: 2020-09-30 Impact factor: 4.677